Bryan D. Smith - Concepedia

Author

Bryan D. Smith

Deciphera Pharmaceuticals (United States)ORCID

Also Known As

B. Smith, B.D. Smith, Brian P. Smith, Bryan A. Smith, Bryan D Smith, Bryan D. Smith, Bryan Douglas Smith, Bryan Smith, Bryan D. Smith, Smith, B.D.

137

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

Deciphera Pharmaceuticals (United States)The University of Texas MD Anderson Cancer Center University of Wisconsin–Madison Oregon Health & Science University Tufts Medical Center

About

Bryan D. Smith is an author at Deciphera Pharmaceuticals (United States) specializing in medicine, pharmacology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	15	1.3K
2	Natural Sciences	6	6	240
3	Engineering	3	3	137
4	Social Sciences	1	1	10
5	Behavioral Sciences	1	1	10

Bryan D. Smith

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers Sheng-Bin Peng, James R. Henry, Michael D. Kaufman, Cancer Cell Ly3009120 LeadsRaf IsoformsMedicineAnti-cancer AgentTumor Suppressor	2015	305
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants Bryan D. Smith, Michael D. Kaufman, Wei-Ping Lu, Cancer Cell Pdgfra VariantsOncogenic AgentMedicineDrug-resistant KitReceptor Tyrosine Kinase	2019	270
Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036 Wayne W. Chan, Scott Wise, Michael D. Kaufman, Cancer Cell Switch-control Inhibitor Dcc-2036Signal TransductionSignaling PathwayConformational Control InhibitionCell Regulation	2011	204
The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors Allison S. Harney, George S. Karagiannis, Jeanine Pignatelli, Molecular Cancer Therapeutics	2017	162
Biomimetic Synthesis of the Putative Cytotoxin Peroxynitrite, ONOO-, and Its Characterization as a Tetramethylammonium Salt D. Scott Bohle, Bernhard Hansert, Scott Paulson, Journal of the American Chemical Society Bioorganic ChemistryToxinologyChemical AnalysisAltmetric Attention ScoreSecondary Metabolite	1994	122
The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile Christopher A. Eide, Lauren T. Adrian, Jeffrey Tyner, Cancer Research	2011	118
Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against <i>BRAF</i> or <i>RAS</i> Mutant Tumor Cells James R. Henry, Michael D. Kaufman, Sheng-Bin Peng, Journal of Medicinal Chemistry Kinase InhibitorsPharmaceutical ChemistryTumor BiologyMolecular PharmacologyMedicinal Chemistry	2015	84
Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2 Bryan D. Smith, Michael D. Kaufman, Cynthia B. Leary, Molecular Cancer Therapeutics Switch Control PocketGliomaTumor BiologyAngiogenesisTumor Initiation	2015	75
Activase Region on Chloroplast Ribulose-1,5-bisphosphate Carboxylase/Oxygenase Bryan D. Smith, Archie R. Portis, Robert J. Spreitzer Journal of Biological Chemistry	2000	65
Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models Yuji Piao, Soon Young Park, Verlene Henry, Neuro-Oncology	2016	65

Page 1